GlassScriptPhysician profile
Amanda K Roberts
NPI 1831363654
$1,232.67
in general payments reported to CMS, 2019-2025
19 companies · $233 in 2025
The $233 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.26 · 2020: $57.49 · 2021: $59.43 · 2022: $179 · 2023: $310 · 2024: $353 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $201.95 | 2020-2024 | Pediarix, Bexsero, Rotarix |
| Pfizer INC. | $188.50 | 2022-2025 | |
| Corium, LLC | $163.23 | 2022-2024 | Azstarys |
| Sanofi Pasteur INC. | $162.79 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $107.00 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $85.67 | 2019-2024 | Jornay Pm |
| Seqirus USA INC | $61.00 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Supernus Pharmaceuticals, INC. | $55.89 | 2022-2025 | Qelbree, Qelbree |
| Abiomed | $28.82 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $23.88 | 2023 | Flumist Quadrivalent |
| Regeneron Healthcare Solutions, INC. | $22.09 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $21.17 | 2019 | |
| Roche Diagnostics Corporation | $18.78 | 2025 | Cobas Liat Analyzer |
| Nestle Healthcare Nutrition INC. | $18.52 | 2023 | |
| Aimmune Therapeutics, INC. | $17.85 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $15.50 | 2023 | Spinraza |
| Phadia US INC. | $14.87 | 2024 | Immunocap |
| Merck Sharp & Dohme LLC | $13.58 | 2022 | |
| Tris Pharma INC | $11.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.